Virupaksha Organics Ltd. has emerged as a leader in the pharmaceutical industry, specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs). Founded in 2003, the company has built a reputation for innovation, quality, and sustainability. Under the dynamic leadership of Mr. Chandra Mouliswar Reddy Gangavaram, Virupaksha has grown its operations significantly, with state-of-the-art manufacturing facilities in Telangana, India.
The company’s facilities in Kazipally and Pashamylaram are certified by international and national regulatory bodies, including ISO 9001, ISO 14001, ISO 45001, ISO 50001, and GMP standards, ensuring that Virupaksha meets the highest levels of quality and safety in its production processes. These certifications highlight the company’s commitment to environmental sustainability, occupational safety, and best industry practices.
Virupaksha Organics is committed to excellence, innovation, and customer satisfaction, with a focus on developing sustainable solutions for the pharmaceutical industry. The company’s products are trusted by major pharmaceutical firms globally, as it continues to make strides towards becoming a research-driven organization. With a forward-thinking management team and a clear vision for the future, Virupaksha Organics is poised for rapid growth and continues to play a key role in advancing global healthcare.
As part of its corporate social responsibility (CSR), Virupaksha has initiated numerous welfare programs aimed at uplifting local communities and supporting environmental conservation, reinforcing its reputation as a responsible corporate citizen.
With continuous advancements and strategic partnerships, Virupaksha Organics Ltd. is well-positioned to expand its global footprint and contribute to the evolving pharmaceutical landscape.
Other Latest News
- CDC's Vaccine Committee Reverses Decades-Long Infant Vaccination Requirement and Subservience to Pharma Red State The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted 8-3 on Friday to put a halt to the quarter-century-old practice of inoculating newborns for an infection associated with high-risk sexual practices and …
- Specials | Dec 05, 2025 | 24 min read ETFs Trading Guide for Indian Traders: Smart Strategies for 2026 Ahmedabad Mirror Indian traders are increasingly turning to ETFs (Exchange-Traded Funds) because they offer diversification, lower risk, and real-time trading — all without the complexities of traditional stock picking. As the Indian markets grow deeper and more …
- <![CDATA[FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL]]> Cancer Network - New Jersey The FDA and European Medicines Agency (EMA) have cleared the global, registrational phase 3 POLARIS trial (NCT06051409), which will be evaluating olverembatinib, an oral third-generation tyrosine kinase inhibitor, in combination with chemotherapy for the …
- AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study WFMZ - Pennsylvania Primary safety and tolerability endpoint met AP-101 prolonged survival and delayed need for ventilatory support after 12 months of treatment Functional stabilization and reduced neurofilament biomarkers observed in study participants with elevated …
- Other news to note for Dec. 5, 2025 BioWorld Biopharma happenings, including deals and partnerships, and other news in brief: Alexion, Alzinova, Atossa, Astrazeneca, Formycon, Jyong, MS Pharma, Neurimmune, Orano, Propanc, Replicate, Roche, Sichuan Kelun, Vycellix. BioWorld Briefs Other news to note
- <![CDATA[PharmTech Weekly News Roundup – Week of December 1, 2025]]> Pharmaceutical Technology In this PharmTech video feature, we highlight the week’s industry news in an easy-to-consume, fun format. New roundups will drop every Friday, so be sure to come back each week. Collectively, the week’s coverage discusses the pharmaceutical industry’s …
- Letter to the editor: War — the user’s guide The Daily Chronicle - Washington State One uniform, flag or insignia against another. In recent years, that distinction has faded away. Today, we are not allowed to distinguish between the bully and the brave. The word “war” is now a term used to describe the annihilation of an entire nation’s …
- Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement Voice of Alexandria - Minnesota Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided …
- Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons EIN Presswire Company announcement – No. 24 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 5, 2025 – Zealand …
- Once-weekly achondroplasia drug boosts annualized growth velocity Healio News December 05, 2025 2 min read Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Children with …
- Fierce Pharma Asia—FDA safety probe of Takeda drug; Otsuka kidney disease nod; ADC patent fight Fierce Pharma The FDA is investigating a safety signal from Takeda’s rare disease med Adzynma. Otsuka won a first-in-class FDA approval to enter the crowded IgA nephropathy field. Daiichi Sankyo won reversal of an unfavorable ruling in its patent fight against Pfizer’s …
- Expert view: Rajesh Palviya of Axis Securities on Nifty 50, Bank Nifty outlook, preferred technical strategy and more Mint Expert view on markets: Rajesh Palviya, SVP - Research, Axis Securities, is positive about the Indian stock market and believes that as long as the Nifty 50 holds above the 25,700–25,900 band, the prevailing directional bias will remain positive. For Bank …
- <![CDATA[Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion]]> Pharmaceutical Executive Mark Cuban has been encouraging the Trump administration to waive the hundreds of thousands of dollars in regulatory fees that often come with generic drug approvals, according to a Reuters report.1 The FDA’s fees for a generic drug approval application …
- Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use BioPharma Dive Today, a brief rundown of news from Praxis Precision Medicines and Bristol Myers Squibb, as well as updates from Denali Therapeutics, Crescent Biopharma and AstraZeneca that you may have missed. Shares of Praxis Precision Medicines surged roughly 40% …
- Rating every men’s WorldTour team’s 2025/2026 transfer window Cyclist With pre-season team camps well underway and jersey reveals on the horizon, the ink is drying on the final WorldTour transfers ahead of the 2026 pro season. This year’s transfer window has been an interesting one, with several high-profile riders cutting …
- Crescent and Kelun-Biotech swap cancer asset rights in double deal Pharmaceutical Technology US company Crescent Biopharma and China-based Kelun-Biotech have partnered to exchange the rights to two of their cancer drugs as they eye clinical trials next year. The strategic partnership sees two separate financial deals for the pair of oncology …
- Business News | India Can Expand Exports to Russia from USD 5 Bn to USD 35 Bn by 2030: GTRI Latestly New Delhi [India], December 5 (ANI): India has the potential to raise its merchandise exports to Russia from about USD 5 billion to nearly USD 35 billion by 2030, according to a GTRI report, as President Vladimir Putin's visit to Delhi places renewed …
- Pharma's trailer shows a sales rep whose fight is against a drug company OTTplay The makers of the upcoming Malayalam web series, Pharma, has finally dropped its trailer today (December 5). The video gives a glimpse into its plot as well as rest of the characters in this series, which will be streaming on JioHotstar and OTTplay Premium …
- The 20 best action movies on Netflix By Ilana Gordon, James Mercadante, and Dennis Perkins Entertainment Weekly Welcome to your mental vacation. We hope you enjoy an action-packed itinerary. Your trip will take you from Japan circa World War II to a dystopian future Earth, and everywhere in between. The characters you'll meet on your journey have little use for …
- Hims and Hers acquires Livewell ahead of generic Ozempic launch in Canada The Kingston Whig-Standard Breadcrumb Trail Links News Almost two-thirds of adults in Canada are overweight or living with obesity, according to the U.S. telehealth company There is currently no generic version of semaglutide on the market that has been approved by Health Canada, …
- COMMENTARY: Top men are on it Cherokee One Feather - North Carolina By ROBERT JUMPER Tutiyi (Snowbird) and Clyde, N.C. We are judged by our actions, or our lack of action. In the public arena, the old saying is “perception is reality”. Public transparency laws are implemented in communities to minimize public speculation …
- Thinking of a pivot? This pharma operations technician got a start in arts Silicon Republic MSD’s Aoife Allen didn’t start out in the pharmaceutical sector, but a natural curiosity and broad skillset stood to her when the time came to make a change. Graduating from UCC in 2023 with an Arts degree in Irish and sociology, Aoife Allen, a process …
- B. Braun Medical Inc. Launches Piperacillin and Tazobactam for Injection and Sodium Chloride Injection in the DUPLEX® Drug Delivery System WFMZ - Pennsylvania BETHLEHEM, Pa., Dec. 5, 2025 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, recently launched Piperacillin and Tazobactam, one of the most utilized injectable antibiotics in the U.S.,1 for …
- How Big Is Pharma’s Carbon Footprint? Highlights From My Green Lab’s 2025 Impact Report Technology Networks Despite economic and political headwinds, companies in the biotechnology and pharmaceutical sectors are still making advances in reducing their greenhouse gas (GHG) emissions. According to a new climate report, a majority of companies have now set medium- …
- Putin India visit live: Modi discusses second Russian nuclear plant in India with Prez Hindustan Times Vladimir Putin India visit live: In a big push for India-Russia nuclear energy cooperation, Russian President Vladimir Putin and Indian Prime Minister Narendra Modi discussed the possibility of building a second nuclear power plant with Russian-designed …
- Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting The AI Journal – Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML – – Findings from the Phase 3 MORPHO trial in the post-transplant maintenance setting …
- Trigent Partners with WeWork India to Expand its GCC Footprint The AI Journal Strategic collaboration accelerates intelligence-driven Global Capability Centers bringing enterprise-grade processes, startup agility, and flexible workspaces SOUTHBOROUGH, Mass., Dec. 5, 2025 /PRNewswire/ — Trigent, a leading technology solutions …
- Daily deucrictibant keeps HAE attack rate low for up to 34 months Healio News December 05, 2025 3 min read Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: The mean attack …
- Protara’s cell therapy touts BCG-naïve treatment potential in Phase II Clinical Trials Arena Protara’s lead candidate, TARA-002, has demonstrated durable complete response (CR) rates in a single-arm Phase II trial in Bacillus Calmette-Guérin (BCG)-naïve non-muscle invasive bladder cancer (NMIBC) patients. During the open-label ADVANCED-2 ( …
- ARCH-backed Paradigm snaps up Flatiron’s clinical research business Clinical Trials Arena US-based clinical trial technology specialist Paradigm Health has agreed to purchase Roche-owned Flatiron Health’s clinical research division. Through this acquisition, Paradigm will integrate Flatiron’s clinical research solutions into its own portfolio …
- Addex Therapeutics Ltd (NASDAQ:ADXN) Q3 2025 Earnings Call Transcript Insider Monkey Addex Therapeutics Ltd (NASDAQ:ADXN) Q3 2025 Earnings Call Transcript December 4, 2025 Operator: Good day, and thank you for standing by. Welcome to the Addex Therapeutics Third Quarter 2025 Financial Results and Corporate Update Conference Call and …
- Business News | Pain-Free Maharashtra Sets GUINNESS WORLD RECORDS ™ Title for Most Joint Health Screenings in 24 Hours Latestly VMPL Mumbai (Maharashtra) [India], December 5: The Mamta & Madhusudan Agrawal Foundation, led by philanthropist Shri Madhusudan Agrawal, Vice Chairman & Co-founder, Ajanta Pharma and Hon. Consul of the Republic of Uganda, has set a Guinness World …
- Five things for pharma marketers to know: Friday, December 5, 2025 Medical Marketing and Media The Centers for Disease Control and Prevention’s vaccine advisory committee has delayed a vote on recommendations for the hepatitis B vaccine until Friday — the third time it’s been postponed. Sen. Bill Cassidy, (R-LA), called ACIP “totally discredited” …
- Here's when an update on Nivin Pauly's web series Pharma will be out! OTTplay The makers of the web series Pharma, starring Nivin Pauly in Malayalam, have revealed an update regarding the release date of the trailer. The first season of PR Arun-directed social drama is expected to appear soon on JioHotstar and OTTplay Premium. The …
- Prasco & Frontier’s tailored logistics: a pharma game-changer FreightWaves Prasco’s new strategic collaboration with Frontier Scientific Solutions marks another example of how pharmaceutical companies are moving beyond traditional 3PL partnerships and opting instead to co-build logistics capabilities tailored specifically for …
- Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Pharma, Inc. Lawsuit – ATYR EIN Presswire NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- NEW YORK, December 4, 2025 – Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: …
- MP Cabinet News: 24 Children Die Due To Coldrif Syrup In 3 Districts, Says Deputy CM Rajendra Shukla Free Press Journal MP Cabinet News: 24 Children Die Due To Coldrif Syrup In 3 Disricts, Says Health Minister Rajendra Shukla | Bhopal (Madhya Pradesh): At least 24 children have died from toxic Coldrif syrup since September 4, with cases reported in Chhindwara, Pandurna, and …
- November Health Winners: Healthcare takes lead on ASX as good news revives sector Stockhead After lagging most of 2025, the ASX healthcare sector was back in favour in November. Pic: Getty Images ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a …
- Trump Administration Eases Investment Deadlines For Large Pharma Companies: Report Asianet Newsable The Trump administration is reportedly easing requirements for large pharmaceutical companies to fulfill some of their investment commitments under the “most favored nation” deals struck with the White House. According to a report by Endpoints News, citing …
- ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure EIN Presswire SAN FRANCISCO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Global plaintiffs’ rights law firm Hagens Berman reminds investors of the December 8, 2025, deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit filed against …
- <![CDATA[Pharma Pulse: Pazdur Retires from FDA, While Public Trusts AMA Over CDC on Vaccines, and New Data Redefines Adherence as an Emotional Crisis]]> Pharmaceutical Commerce Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines. First up, …
- Business News | India's Pharma Sector Emerging as Global Generics Powerhouse, Need to Scale AI Usage Beyond R&D: Report Latestly New Delhi [India], December 4 (ANI): India has transformed from a medicine importer into a global generics powerhouse in the last five decades producing over 60,000 generic drugs across over 60 therapeutic categories and exporting to over 200 countries, …
- I worked for Big Pharma. I know why we got the… USA Today Dec. 4, 2025, 6:01 a.m. ET A year ago, I was one of the top spokespeople for the pharmaceutical industry as the chief public affairs officer for the Biotechnology Innovation Organization. It was there I'd spent years creating communications strategies …
- Five things for pharma marketers to know: Thursday, December 4, 2025 Medical Marketing and Media OpenAI CEO Sam Altman’s longevity startup Retro Bio is seeking to raise a $5 billion valuation, which could make it one of the drug industry’s biggest investment rounds. The startup’s goal is to add 10 years to the human lifespan through epigenetic editing …
- Business News | Stock Markets Open Flat Amid External Pressure, RBI Policy Outcome to Provide Further Direction Latestly Mumbai (Maharashtra) [India], December 4 (ANI): The domestic benchmark indices opened flat on Thursday as bulls and bears attempted to pull the markets towards their sides amid external pressure, even as domestic indicators offered support. The Nifty 50 …
- Stocks in news: IndiGo, RIL, JSW Steel, Pine Labs, ONGC The Economic Times Markets witnessed a volatile session and ended marginally lower, extending the ongoing consolidation phase. Sentiment was dampened by a weakening rupee, which hit a record low of 90.13 against the dollar, heightening concerns around import costs and …
- STAT+: Pharmalittle: We’re reading about FDA’s Pazdur retiring, Europe’s reaction to U.S.-U.K. pharma deal, and more STAT - Massachusetts Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the …
- <![CDATA[Pharma Pulse: Long COVID Exercise Win, $150M Gene Editing Play, and Compounding Pharmacy Expansions]]> Pharmaceutical Commerce Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines. First, we …
- Biologics CDMO Market Trends and Investment Forecast to 2033: Features Analysis of Lonza Group, Catalent Pharma Solutions, Samsung Biologics and Other Key Industry Players - ResearchAndMarkets.com Voice of Alexandria - Minnesota DUBLIN--(BUSINESS WIRE)--Dec 3, 2025-- The "Biologics Contract Development and Manufacturing Organization Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering. The global biologics contract development and …
- Win for pharma in UK – zero US tariffs, VPAG rate cap and NICE threshold increase Pharmaceutical Technology On 1 December, the fortunes of the UK pharma sector changed radically, with the UK Government becoming the first in the world to secure a 0% US import tariff on pharmaceuticals. However, while zero tariffs may give UK pharma companies such as GSK and …